"Neuroprotective Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids.
| Descriptor ID |
D018696
|
| MeSH Number(s) |
D27.505.696.706.548 D27.505.954.427.575
|
| Concept/Terms |
Neuroprotective Agents- Neuroprotective Agents
- Agents, Neuroprotective
- Neuroprotectants
- Neuroprotective Drugs
- Drugs, Neuroprotective
Neuroprotective Effect- Neuroprotective Effect
- Effect, Neuroprotective
- Neuroprotective Effects
- Effects, Neuroprotective
|
Below are MeSH descriptors whose meaning is more general than "Neuroprotective Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuroprotective Agents".
This graph shows the total number of publications written about "Neuroprotective Agents" by people in this website by year, and whether "Neuroprotective Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 4 | 2 | 6 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2006 | 2 | 0 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 5 | 1 | 6 |
| 2011 | 2 | 2 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 4 | 2 | 6 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 0 | 3 |
| 2020 | 3 | 0 | 3 |
| 2021 | 0 | 1 | 1 |
| 2023 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuroprotective Agents" by people in Profiles.
-
Mortality in Women across the FMR1 CGG Repeat Range: The Neuroprotective Effect of Higher Education. Cells. 2023 08 24; 12(17).
-
The Evolution of Ketamine in Severe Pediatric Traumatic Brain Injury, From Contraband to Promising Neuroprotectant? Crit Care Med. 2023 05 01; 51(5):677-680.
-
Why ketamine. Epilepsy Behav. 2023 04; 141:109066.
-
A Detailed Analysis of Infarct Patterns and Volumes at 24-hour Noncontrast CT and Diffusion-weighted MRI in Acute Ischemic Stroke Due to Large Vessel Occlusion: Results from the ESCAPE-NA1 Trial. Radiology. 2021 07; 300(1):152-159.
-
Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARa-Dependent Astrocytic GDNF Pathway. J Neurosci. 2021 03 10; 41(10):2287-2300.
-
Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications. J Neurol Neurosurg Psychiatry. 2021 02; 92(2):177-188.
-
RNS60, a physically-modified saline, inhibits glial activation, suppresses neuronal apoptosis and protects memory in a mouse model of traumatic brain injury. Exp Neurol. 2020 06; 328:113279.
-
Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020 03 14; 395(10227):878-887.
-
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020; 10(3):875-891.
-
PPARa serves as a new receptor of aspirin for neuroprotection. J Neurosci Res. 2020 04; 98(4):626-631.